Hanall Biopharma Reports 26.2 Billion KRW in Q2 Sales... Growth in Key Products

[Asia Economy Reporter Lee Gwan-joo] HanAll Biopharma announced on the 28th that its consolidated sales for the second quarter of this year amounted to 26.2 billion KRW, with an operating profit of 700 million KRW. Sales increased by 12% compared to the same period last year, and operating profit turned positive from a loss in the previous quarter.

The company explained that its main products, including the enteritis treatment 'Normix', prostate cancer treatment 'Eligard', probiotics 'BioTop', and hair loss treatments 'Hairgro' and 'Adamo', have maintained a steady growth rate of over double digits. Recently, new launches such as the diabetes treatment 'Glucopree' and gastroesophageal reflux disease treatment 'Absito Tablet' are expected to boost pharmaceutical sales.

As of the end of the first half, HanAll Biopharma maintains a stable financial structure with consolidated assets of 183 billion KRW, equity of 150.2 billion KRW, and liabilities of 32.8 billion KRW, resulting in a debt ratio of 22%. The company reinvests profits generated from pharmaceutical sales and technology fees into R&D, maintaining a virtuous cycle of R&D that generates greater profits.

Park Seung-guk, CEO of HanAll Biopharma, stated, "Pharmaceutical sales growth continued in the second quarter, and we expect to sustain steady growth in the future due to recently launched new products."

Various pipelines are also progressing smoothly. The autoimmune disease treatment antibody drug 'HL161' is undergoing clinical development in the US and China by Immunovant and Harbormed, respectively. Immunovant initiated a Phase 3 clinical trial for HL161 in myasthenia gravis in the US last month, while Harbormed is conducting clinical trials in China for myasthenia gravis as well as thyroid eye disease (TED), immune thrombocytopenia (ITP), neuromyelitis optica (NMO), and chronic inflammatory demyelinating polyneuropathy (CIDP).

The dry eye treatment 'HL036' is currently in its second Phase 3 clinical trial in the US. HL186 and HL187 are immune-oncology antibody candidates targeting TIM-3 and TIGIT, respectively, and have now confirmed candidate antibodies and entered the preclinical stage. HanAll Biopharma and Daewoong Pharmaceutical are jointly investing, with Samsung Biologics participating as a CDMO, responsible for cell line and CMC development as well as manufacturing clinical trial materials.

This content was produced with the assistance of AI translation services.